Dirk Van Hyfte

Founded in 2019, BioClue BV is a subsidiary of ImmunoPrecise Antibodies Ltd. that provides biotechnology services and specializes in the development of antibody therapeutics. The company is based in Hamont-Achel, Belgium.

Part of ImmunoPrecise Antibodies Ltd., BioKey BV is a company based in Hamont-Achel, Belgium.

Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million.

Part of ImmunoPrecise Antibodies Ltd., BioKey BV is a company based in Hamont-Achel, Belgium.

Founded in 2019, BioClue BV is a subsidiary of ImmunoPrecise Antibodies Ltd. that provides biotechnology services and specializes in the development of antibody therapeutics. The company is based in Hamont-Achel, Belgium.

Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million.

Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million.

Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million.